Clovis Oncology Inc (CLVS) Gross Profit Margin starting from the third quarter 2022 to third quarter 2021, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Clovis Oncology inc   (NASDAQ: CLVS)


Clovis Oncology Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CLVS Gross Profit Margin (Sep 30 2022)
Q3 		(Jun 30 2022)
Q2 		(Mar 31 2022)
Q1 		(Dec 31 2021)
Q4 		(Sep 30 2021)
Q3
Y / Y Revenue Change -19.13 %
Seq. Revenue Change -4.6 %
Revenue In Millions $30.66
Gross Profit Margin 76.31 %
Gross Profit Margin Total Ranking # 837
Gross Profit In Millions $23.40
Y / Y Gross Profit Change -20.44 %
Seq. Gross Profit Change -3.6 %


Commenting Third Quarter 2022 Gross Profit Margin
Clovis Oncology inc increased Gross Profit Margin through reduction in Cost of Sales and despite contraction in Gross Profit by -3.6 % and Revenue by -4.6 %. Gross Profit Margin in Q3 was 76.31 %, below company average.


Observing third quarter 2022 results within Major Pharmaceutical Preparations industry 78 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 720 to 837.
Learn about Gross Margin
CLVS's Gross Profit Margin third quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 79
Healthcare Sector # 147
Overall # 820

Gross Profit Margin Statistics
High Average Low
97.83 % 78.45 % 10.26 %
  (Dec 31 2016)


CLVS Gross Income Trends • More of CLVS's Profitabilty Ratios • CLVS Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
CLVS's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
CLVS's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for CLVS's Competitors
Gross Profit Margin Profit Margin for Clovis Oncology Inc 's Suppliers
Gross Profit Margin Profit Margin for CLVS's Customers

You may also want to know
CLVS's Annual Growth Rates CLVS's Profitability Ratios CLVS's Asset Turnover Ratio CLVS's Dividend Growth
CLVS's Roe CLVS's Valuation Ratios CLVS's Financial Strength Ratios CLVS's Gross Profit Growth
CLVS's Roa CLVS's Inventory Turnover Ratio CLVS's Growth Rates CLVS's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2022, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2022 MRQ Gross ProfitSep 30 2022 MRQ Revenue
Ptc Therapeutics inc   99.86 %$ 216.827  Millions$ 217.127  Millions
Intercept Pharmaceuticals inc   99.45 %$ 77.164  Millions$ 77.588  Millions
Chimerix Inc   98.98 %$ 32.222  Millions$ 32.555  Millions
Rigel Pharmaceuticals Inc  98.88 %$ 22.160  Millions$ 22.410  Millions
Corcept Therapeutics Inc  98.68 %$ 100.389  Millions$ 101.728  Millions
Acadia Pharmaceuticals Inc   98.37 %$ 128.578  Millions$ 130.714  Millions
Marinus Pharmaceuticals Inc   97.95 %$ 2.292  Millions$ 2.340  Millions
Tg Therapeutics Inc   97.87 %$ 0.092  Millions$ 0.094  Millions
Karyopharm Therapeutics Inc   97.29 %$ 35.165  Millions$ 36.145  Millions
Precigen Inc   97.23 %$ 16.259  Millions$ 16.722  Millions
2seventy Bio Inc   97.19 %$ 13.031  Millions$ 13.408  Millions
Durect Corp  97.12 %$ 11.632  Millions$ 11.977  Millions
Travere Therapeutics Inc   96.87 %$ 51.821  Millions$ 53.496  Millions
Avalo Therapeutics Inc   96.47 %$ 14.421  Millions$ 14.949  Millions
Aurinia Pharmaceuticals Inc   95.61 %$ 53.332  Millions$ 55.779  Millions
Myovant Sciences Ltd   95.29 %$ 99.882  Millions$ 104.824  Millions
Regeneron Pharmaceuticals Inc   95.19 %$ 2,794.900  Millions$ 2,936.200  Millions
Aclaris Therapeutics Inc   95.15 %$ 18.095  Millions$ 19.018  Millions
Zevra Therapeutics Inc   95.09 %$ 2.733  Millions$ 2.874  Millions
Siga Technologies Inc  94.53 %$ 68.262  Millions$ 72.211  Millions
Innoviva Inc   94.53 %$ 63.577  Millions$ 67.257  Millions
Albireo Pharma inc   93.78 %$ 9.220  Millions$ 9.832  Millions
Cti Biopharma Corp   93.68 %$ 17.089  Millions$ 18.241  Millions
Kiniksa Pharmaceuticals International Plc  93.00 %$ 92.198  Millions$ 99.135  Millions
Macrogenics Inc   92.79 %$ 38.727  Millions$ 41.734  Millions
United Therapeutics Corporation  92.79 %$ 478.800  Millions$ 516.000  Millions
Bioxcel Therapeutics Inc   91.97 %$ 0.126  Millions$ 0.137  Millions
Silo Pharma Inc  91.91 %$ 0.017  Millions$ 0.018  Millions
Arvinas Inc   91.27 %$ 30.300  Millions$ 33.200  Millions
Ocular Therapeutix Inc   91.03 %$ 10.892  Millions$ 11.965  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.